Hyperion Defi, Inc. · NASDAQ:HYPD
Hyperion Defi — Eyenovia — Investor Presentation (October 2019)
12 slides from Hyperion Defi's investor presentation, Oct 29, 2019
Slide 1: Making it Possible October 2019
Making it Possible October 2019
Slide 2: Forward-Looking Statements
Except for historical information, all of the statements, expectations, and assumptions contained in this presentation are forward - looking statements . Forward - looking statements include, but are not limited to, statements that express our intentions, beliefs, expectations, strategies, predictio
Slide 3: Eyenovia: Building the Smart Eye Care Company of the Future
Eyenovia: Building the Smart Eye Care Company of the Future • Eyenovia is building a robust late - stage pipeline in ophthalmology …with next generation, intelligent µ - therapeutics • Initiated 2 Phase III programs in last 12 months – MICROPINE: First - in class back - of - the - eye therapeutic pr
Slide 4: Eyenovia Updated Pipeline: Prioritize Presbyopia Phase III Program
Eyenovia Updated Pipeline: Prioritize Presbyopia Phase III Program • PRESBYOPIA: Prioritize MicroLine for the pharmacologic treatment of presbyopia – Initiate and complete MicroLine Phase III VISION study in 2020 • MYOPIC PROGRESSION: Continue CHAPERONE Ph III trial with complete enrollment in 2020
Slide 5: Multiple Late Stage Clinical Assets
4 Multiple Late Stage Clinical Assets Back - of - the - eye Indications Front - of - the - eye Indications Preclinical/Formulation Phase I Phase II Phase III Anticipated 2020 Milestones Micro Pine Reduction of Pediatric Myopia Progression CHAPERONE Enrollment Completion Micro Line Improvement in nea
Slide 6: Why MicroLine?
5 Why MicroLine ? Glaucoma US Market $1.5Bn MicroProst Addressable Market $150 - 200M Phase III Results H2 2020 FDA Approval est. H1 2022 Presbyopia US Market $ Bn MicroLine Addressable Market $ M Phase III Results H2 2020 FDA Approval est. H1 2022 MicroProst for Glaucoma (CACG+OAG+OHT) MicroLine fo
Slide 7: Presbyopia: the Progressive Loss of Ability to Focus on Nearby Objects
Etiology • Non - preventable, age - related hardening of the lens Symptoms • Tendency to hold reading material farther away to make the letters clearer • Blurred vision at normal reading distance • Eye strain , headaches after reading or doing close - up work Risk Factors • Age • Medical conditions
Slide 8: Presbyopia is a Widely Prevalent Vision Correction Issue
• Prevalence expected to increase and affect ~123 million Americans by 2020, representing over 1/3 of U.S. population; driven by aging population • Nearly everyone experiences some degree of presbyopia after age 40 • Up to 1/3 of presbyopia sufferers are un - managed • Presbyopia is a significant an
Slide 9: MicroLine: Pharmacologic Treatment of Presbyopia
Indication • For the Improvement in near vision in patients with presbyopia • Provides approximately 3 - 4 hours of near vision with a single microRx spray Program Overview • 2 Phase III trials ready for initiation in 2020 Commercial • Estimated addressable population: Adults between 40 - 65 years o
Slide 10: MicroLine Phase III Program
9 MicroLine Phase III Program • Two double - masked, placebo - controlled, cross - over superiority trials – Phase III (microdosed pilocarpine 1.0%, 2.0% and placebo) • Primary endpoint: binocular distance corrected near visual acuity VISION 1 Screening Age 40 – 60 With Presbyopia VISION 2 Screening
Slide 11: Eyenovia Can Lead the Way in Presbyopia
10 Eyenovia Can Lead the Way in Presbyopia … Company Compound Active Stage MicroLine Pilocarpine piezo - formulation Phase III Pilocarpine Pilocarpine formulation Phase III PRX - 100 Aceclidine + Tropicamide Phase IIb Presbi - Drops Pilocarpine + NSAID Phase II UNR844 Lipoic acid choline ester 1.5%
Slide 12: Making it Possible October 2019
Making it Possible October 2019